Inhibitory effect of bombesin/gastrin-releasing peptide (GRP) antagonists RC-3950-II and RC-3095 on MCF-7 MIII human breast cancer xenografts in nude mice

Y. Shirahige, Renzhi Cai, K. Szepeshazi, G. Halmos, J. Pinski, K. Groot, A. V. Schally

Research output: Contribution to journalArticle

25 Scopus citations

Abstract

Bombesin/gastrin-releasing peptide (GRP) may be involved in the growth of human breast cancers. Nude mice bearing xenografts of MCF-7 MIII human breast cancer cell line were treated for 7 weeks with bombesin/GRP antagonists RC-3950-II and RC-3095. RC-3950-II, administered sc twice daily at a dose of 10 μg, produced significant inhibitory effects on tumor growth after 2 weeks of administration. RC-3095 acetate (D 22213), injected sc twice daily at the same dose of 10 μg, suppressed tumor growth after 4 weeks. Both RC-3950-II and RC-3095 significantly decreased the final tumor volume and tumor weights. RC-3950-I1 appeared to be somewhat more efficacious than RC-3095 in inhibiting the growth of MCF-7 MIII breast cancers. Chronic treatment with either bombesin/GRP antagonist caused down-regulation of receptors for epidermal growth factor (EGF) in tumor cell membranes, which might be related to inhibition of tumor growth. These findings suggest that bombesin/GRP antagonists should be considered for a new endocrine therapy of breast cancer.

Original languageEnglish (US)
Pages (from-to)465-472
Number of pages8
JournalBiomedicine and Pharmacotherapy
Volume48
Issue number10
DOIs
StatePublished - 1994
Externally publishedYes

Keywords

  • bombesin
  • breast cancer
  • EGF-receptor
  • GRP antagonists

ASJC Scopus subject areas

  • Pharmacology

Fingerprint Dive into the research topics of 'Inhibitory effect of bombesin/gastrin-releasing peptide (GRP) antagonists RC-3950-II and RC-3095 on MCF-7 MIII human breast cancer xenografts in nude mice'. Together they form a unique fingerprint.

  • Cite this